CABA Rese-cel CAR-T data highlights safety and scalable manufacturing
Rese-cel’s nine-day CAR-T process reported strong safety and efficacy in autoimmune diseases, with over 90 patients treated and no IEC-HS events. Dual-source manufacturing and outpatient protocols are part of the scale-up plan.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.